Dimesna

• Description :

  Dimesna combined with anticancer chemotherapeutic agents to reduce nephrotoxicity.

• Product Name Alternative :

  BNP-7787

• UNSPSC :

  12352100

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Drug Metabolite

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Dimesna.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : 68 mg/mL (ultrasonic; warming) |H2O : 100 mg/mL (ultrasonic)

• Smiles :

  O=S(CCSSCCS(=O)(O[Na])=O)(O[Na])=O

• Molecular Formula :

  C4H8Na2O6S4

• Molecular Weight :

  326.34

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Parker AR, et al. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro. Mol Cancer Ther. 2010 Sep;9 (9) :2558-2567.|[2]Hausheer FH, et al.Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol. 2010 Apr;65 (5) :941-951.|[3]Cutler MJ, et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52 (4) :530-542.|[4]Habs MR, et al. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna) . Cancer. 1983 Feb 15;51 (4) :606-609.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [16208-51-8]